These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25596540)

  • 21. Targeting oncogenic drivers and the immune system in melanoma.
    McArthur GA; Ribas A
    J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
    Ascierto PA; Flaherty K; Goff S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():751-758. PubMed ID: 30231371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. State of Melanoma: An Historic Overview of a Field in Transition.
    Karapetyan L; Kirkwood JM
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):1-27. PubMed ID: 33759768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melanoma: from darkness to promise.
    Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
    Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Combinations as the New Standard for Melanoma Treatment.
    Polkowska M; Czepielewska E; Kozłowska-Wojciechowska M
    Curr Treat Options Oncol; 2016 Dec; 17(12):61. PubMed ID: 27766547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.
    Tomei S; Wang E; Delogu LG; Marincola FM; Bedognetti D
    Expert Opin Biol Ther; 2014 May; 14(5):663-86. PubMed ID: 24625306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Melanoma CNS Metastases.
    Jang S; Atkins MB
    Cancer Treat Res; 2016; 167():263-79. PubMed ID: 26601867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
    Aris M; Barrio MM
    Front Immunol; 2015; 6():46. PubMed ID: 25709607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
    Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
    Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma.
    Sullivan RJ; Flaherty KT
    Nat Rev Clin Oncol; 2015 Nov; 12(11):625-6. PubMed ID: 26416151
    [No Abstract]   [Full Text] [Related]  

  • 33. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.
    Sullivan RJ; Lorusso PM; Flaherty KT
    Clin Cancer Res; 2013 Oct; 19(19):5283-91. PubMed ID: 24089441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma.
    Matikas A; Mavroudis D
    Future Oncol; 2015; 11(6):997-1009. PubMed ID: 25760979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major therapeutic developments and current challenges in advanced melanoma.
    Sullivan RJ; Flaherty KT
    Br J Dermatol; 2014 Jan; 170(1):36-44. PubMed ID: 24443912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular-target therapy for advanced malignant melanoma].
    Takahashi S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):19-25. PubMed ID: 23306915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the treatment of malignant melanoma.
    Krementz ET; Creach O
    Proc Natl Cancer Conf; 1970; 6():529-42. PubMed ID: 5458120
    [No Abstract]   [Full Text] [Related]  

  • 39. [Adjuvant and palliative therapy of melanoma. Current status].
    Tilgen W
    Chirurg; 1994 Mar; 65(3):153-63. PubMed ID: 7514966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know.
    Chen M; Smith DA; Yoon JG; Vos D; Kikano EG; Tirumani SH; Ramaiya NH
    J Comput Assist Tomogr; 2022 Jul-Aug 01; 46(4):621-632. PubMed ID: 35675685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.